A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
333actual
Sites
128
Countries
Argentina, Australia, Brazil +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-09 | actual | When the study began enrolling |
| Primary completion | 2026-01-12 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-01-21 | estimated | The whole study's end, after follow-up |
| First posted | 2023-10-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced or Metastatic Breast Cancer
Interventions
- Drug: PF-07220060 CDK4 inhibitor
- Drug: Fulvestrant
- Drug: Everolimus
- Drug: Exemestane
Primary outcome
what the primary-completion date above is the date OFProgression-Free Survival (PFS) progression, as determined by investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
measured From Initiation up to 2 years
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed